CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Registration for the 2019 Canadian Cancer Research Conference (CCRC) is now open.The conference will be of interest to cancer researchers, clinicians, and decision-makers across disciplines and at all stages of their career.
The Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100) was published online today, August 20, 2019 and can be found on the Health Canada website at:
The CCTG Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has a job opening for a two Study Coordinators and a Research Associate.
CCTG Director, Dr Janet Dancey will be a Keynote Speaker at the The 5th International Clinical Trials Methodology Conference is being held 6-9th October 2019 in Brighton UK. Dr Dancey will be speaking on the The Evolution of Academic Sponsored Clinical Trials in the 21st Century: Lessons Learned at the Canadian Cancer Trials Group.
The Canadian Cancer Trials Group's (CCTG) Head and Neck Executive Committee (HNEC) is currently seeking individuals with interest and experience in head and neck studies to join the HNEC. In broad terms (adapted from the CCTG's Terms of Reference), the roles of the Disease Site Committee (DSC) Executive members are to:
Carol is a cancer survivor who was treated for metastatic gynecologic cancer in 2013. She has a network of other cancer survivors and patients who support each other during their cancer journeys. Today, Carol is currently a CCTG patient representative for the CCTG Gynecology, Economic Analysis and Clinical Trials committees. Carol is also the Managing Director, Audit Services at Ontario Teachers Pension Plan. Her career has included roles in finance, information technology, investments, risk management, external audit and (now) internal audit.
The Canadian Cancer Trials Group is seeking a Physician trained in a cancer-related specialty to join our research group as a Senior Investigator in the Investigational New Drug (IND) Program.
It is with great sadness that CCTG shares the news of the passing of Aldo Del Col, a valued member of the CCTG Patient Representative Committee and the Hematology Disease Site Committee. He worked tirelessly to ensure that the patient voice was part of the design and conduct of CCTG clinical trials.
